Journals / Kafkas Üniversitesi Veteriner Fakültesi Dergisi / 2012 / Cilt: 18 - Sayı: 0

Leishmania tropica Promastigotları ve Amastigotları Üzerine Azitromisin ve Klaritromisinin in vitro Etkisi

The in vitro Effects of Azithromycin and Clarithromycin on Promastigotes and Amastigotes of Leishmania tropica

Pages
115–120
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In vivo studies should be planned to detect intracellular concentrations of these drugs for the effective route and dosage

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Leishmania (L.) tropica is one of the most common species responsible for cutaneous leishmaniasis (CL) in the Old World including Turkey.
📊
Key Findings & Data:The pentavalent antimonials are widely used as intralesional and/or intramuscular in the treatment of CL, but increase in resistance to these agents led to investigations on alternative drugs.
💡
Conclusion & Impact:In vivo studies should be planned to detect intracellular concentrations of these drugs for the effective route and dosage
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Leishmania (L.) tropica is one of the most common species responsible for cutaneous leishmaniasis (CL) in the Old World including Turkey. The pentavalent antimonials are widely used as intralesional and/or intramuscular in the treatment of CL, but increase in resistance to these agents led to investigations on alternative drugs. In vitro antileishmanial activities of two macrolides, azithromycin and clarithromycin were evaluated on promastigotes in RPMI 1640 medium and amastigotes in macrophage series of L. tropica. ED50 values of azithromycin and clarithromycin were found to be 5 µg/ml and <5 µg/ml on promastigotes, and 50-75 µg/ml and <3 µg/ml on amastigotes, respectively, while ED90 values of the same drugs were 75 µg/ml and 25 µg/ml on promastigotes and 100 µg/ml and 10 µg/ml on amastigotes, respectively. Our data suggested that clarithromycin and azithromycin were effective on both L. tropica promastigotes and amastigotes in vitro. Clarithromycin was found to be more effective than azithromycin at lower concentrations on promastigotes and amastigotes. In vivo studies should be planned to detect intracellular concentrations of these drugs for the effective route and dosage

Özet

Leishmania (L.) tropica, Türkiye'de dahil olmak üzere Eski Dünya'da kutanöz leishmaniasisden (KL) sorumlu en önemli türdür. KL tedavisinde intralezyoner ve intramuskuler yoldan beş değerlikli antimon bileşikleri yaygın olarak kullanılmaktadır, fakat bu ajanlara karşı artan direnç alternatif ilaçların geliştirilmesini gerekli kılmaktadır. Bu çalışmada, makrolid grubundan iki antibiyotik olan azitromisin ve klaritromisinin L. topica'nın RPMI 1640 besiyerindeki promastigotlar ve makrofaj serisindeki amastigotlar üzerine olan antileishmanial aktiviteleri değerlendirilmiştir. Azitromisin ve klaritromisinin promastigotlar üzerindeki ED50 değerleri sırasıyla 5 µg/ml ve <5 µg/ml olarak, amastigotlar üzerindeki ED50 değerleri sırasıyla 50-75 µg/ml ve <3 µg/ml olarak bulunurken ED90 değerleri promastigotlar üzerinde 75 µg/ml ve 25 µg/ml olarak, amastigotlar üzerinde ise 100 µg/ml ve 10 µg/ml olarak bulunmuştur. Bu çalışmada, azitromisin ve klaritromisinin in vitro olarak L. tropica promastigot ve amastigotları üzerine etkili olduğu gösterilmiştir. Klaritromisin her iki parazit formunda da daha düşük dozlarda azitromisinden daha etkili olduğu belirlenmiştir. Bu ilaçların kullanım şekli ve dozajlarının belirlenmesi için hücre içi konsantrasyonlarının saptanması amacıyla in vivo çalışmaların planlanması gerektiği kanısına varılmıştır

🔖

Cite This Article

BALCIOĞLU, İ. C., OK, Z. Ü., ÖZBEL, Y., GİRGİNKARDEŞLER, N., ÖZBİLGİN, A. (2012). Leishmania tropica Promastigotları ve Amastigotları Üzerine Azitromisin ve Klaritromisinin in vitro Etkisi. Kafkas Üniversitesi Veteriner Fakültesi Dergisi, Cilt: 18 - Sayı: 0, 115–120. https://ajindex.com/articles/272993

References (11)

  1. Molyneux DH, Killick-Kendrick R: Morphology, ultrastructure and lifecycles. In, Peters W, Killick-Kendrick R (Eds): The Leishmaniases in Biology and Medicine. Vol. 1. Biology and Epidemiology, pp. 1-120,
  2. Academic Press, London, 1987.
  3. Seaman J, Mercer J, Sondorp HE, Herwaldt BL: Epidemic visceral leishmaniosis in Southern Sudan: Treatment of severely debilitated patients under wartime conditions and with limited resources. Ann Intern Med, 124, 664-672, 1996.
  4. Hewitt S, Reyburn H, Ashford R, Rowland M: Anthroponotic cutaneous leishmaniasis in Kabul, Afghanistan: Vertical distribution of cases in apartment blocks. Trans R Soc Trop Med Hyg, 92 (3): 273-274, 1998. Berman JD: Chemotherapy for leishmaniasis: Biochemical mechanisms, clinical efficacy, and future strategies. Rev Infect Dis, 10, 560-586, 1988.
  5. Araujo FG, Shepard RM, Remington JS: In vivo activity of the macrolide antibiotics azithromycin, roxithromycin and spiramycin against Toxoplasma gondii. Eur J Clin Microbiol Infect Dis, 10, 519-524, 1991.
  6. Brun-Pascaud M, Rajagopalan-Levasseur P, Chau F, Bertrand G, Garry L, Derouin F, Girard PM: Drug evaluation of concurrent Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium complex infections in a rat model. Antimicrob Agents Chemother, 42 (5): 1068-1072, 1998.
  7. Giacometti A, Cirioni O, Scalise G: In vitro activity of macrolides alone and in combination with artemisin, atovaquone, dapsone, minocycline or pyrimethamine against Cryptosporidium parvum. J Antimicrob Chemother, (3): 399-408, 1996.
  8. Hicks P, Zwiener RJ, Squires J, Savell V: Azithromycin therapy for Cryptosporidium parvum infection in four children infected with human immunodeficiency virus. J Pediatr, 129, 297-300, 1996.
  9. Taylor WR, Richie TL, Fryauff DJ, Picarima H, Ohrt C, Tang D, Braitman D, Murphy GS, Widjaja H, Tjitra E, Ganjar A, Jones TR, Basri H, Berman J: Malaria prophylaxis using azithromycin: A double-blind, placebo-controlled trial in Irian Jaya, Indonesia. Clin Infect Dis, 28, 74-81, 1999.
  10. Krolewiecki A, Leon S, Scott P, Abraham D: Activity of azithromycin against Leishmania major in vitro and in vivo. Am J Trop Med Hyg, 67 (3): 277, 2002.
  11. Mallison DJ, Coombs GH: Interaction of Leishmania metacyclics with macrophages. Int J Parasitol, 19 (6): 647-656, 1989. Berman JD: Treatment of New World cutaneous and mucocutaneous leishmaniasis. Clin Dermatol, 14, 519-522, 1996. Berman JD: Human leishmaniasis: Clinical, diagnostic and chemo- therapeutic developments in the last 10 years.